HXE Facts
Dissociative;
Description
HXE (hydroxetamine) is a synthetic dissociative of the arylcyclohexylamine class. It is the primary metabolite of methoxetamine, and roughly twice as potent at the NMDA.[1] It blocks glutamate signaling in the brain, producing the disconnection from body and environment characteristic of dissociative drugs.
HXE was first identified in 2013 as a breakdown product of Methoxetamine, not as a drug in its own right.[2] Progressive international scheduling of MXE created a market vacuum that HXE filled when it appeared as a standalone substance in late 2019. It now circulates on unregulated markets and has been linked to deaths since 2021,[3] with drug monitoring agencies actively tracking it.
Subjective effects include dissociation, pain suppression, warmth, derealization, and visual distortion. The experience has a sedating, enveloping quality — lower doses bring mild stimulation and perceptual softening, while higher doses produce deep immersive internal states where the surroundings largely disappear. Confusion, impaired coordination, and a compulsive compulsive redosing urge are common unwanted effects.
Dependence liability is moderate, inferred from ketamine-class data; no lethal dose has been established in any species. The greatest danger comes from combinations — mixing with stimulants has proven fatal in the class, and adding depressants amplifies sedation and respiratory depression. HXE is among the least-studied dissociatives in active use — one electrophysiological study and forensic case reports make up its entire evidence base.
Dose and durationby route · individual sensitivity varies
Starts in 20 – 60 minLasts 3 – 8 hoursAfter-effects 1 – 12 hours
Body and dependence
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Physical dependence
- Low
- Psychological dependence
- Moderate
- Withdrawal
- None recorded
- Compulsive redosing
- Moderate
Tolerance
- Builds
- Moderate
- Fully resets after
- 1.5 weeks
- Carries over to
- ketamine;
methoxetamine; PCP; dextromethorphan; deschloroketamine
Effectslikely at a common dose
- Perception
- none likely · 30 possible, including Spatial disorientation, Double vision, Visual acuity suppression
- Body
- none likely · 31 possible, including Dizziness, Motor control impairment, Nystagmus (eye wobbles)
- Thinking
- none likely · 28 possible, including Memory suppression, Cognitive impairment, Compulsive redosing urge
- Feeling
- none likely · 8 possible, including Emotional lability, Anxiety, Empathy suppression
- Self
- none likely · 8 possible, including Depersonalization, Derealization, Communication suppression
- Time
- none likely · 5 possible, including Temporal disorientation
- Awareness
- none likely · 2 possible
Who shouldn't take it
Combinations60 recorded
Seek help immediately if
- Severe disorientation; unable to move or speak (deep dissociation / "k-hole")
- Complete loss of coordination — cannot stand or walk safely
- Vomiting while incapacitated (choking / aspiration risk)
- Very high blood pressure; fast heart rate
- Slow or shallow breathing at high doses (especially mixed with depressants)
- Unconsciousness; rarely, seizures
What to do
- Move them somewhere safe, away from stairs, water, roads, and sharp edges — they cannot protect themselves
- Place in the recovery position if vomiting or unconscious (aspiration is a key risk)
- Stay with them and reassure calmly; keep the environment quiet
- If breathing is slow/shallow or they are unresponsive, call emergency services
- Do not let them wander; do not leave them alone
- Be ready to give rescue breaths / CPR
Effects wear off with time in a safe, monitored setting. The main dangers are physical injury and aspiration while incapacitated, and respiratory depression when combined with other depressants — not the dissociation itself.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]^Irie T, Yanase Y, Demizu Y, Usami M, Kikura-Hanajiri R (2022) Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors — Journal of Pharmacological Sciences doi:10.1016/j.jphs.2022.09.005
- [2]^Meyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH (2013) Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn — Analytical and Bioanalytical Chemistry doi:10.1007/s00216-013-7051-6
- [3]